Clarithromycin — How Dangerous It Is, Side Effects and Contraindications

EFFECTIVE | TOXIC

Names Under Which Clarithromycin Is Found

The international nonproprietary name is clarithromycin; the Latin spelling is clarithromycin. In documents and search queries, the forms “кларитромицин” and “clarithromycin” are encountered, with the transliteration “clarithromycinum” used less often. The active substance is a semisynthetic derivative of erythromycin; finished medicinal products usually list clarithromycin directly, without a separate name for the salt. The main dosage forms are immediate-release tablets, extended-release tablets, granules or powder for preparation of an oral suspension, and, in some countries, formulations for intravenous administration. The best-known brand names include Klacid, Biaxin, Klaricid, Fromilid, Klarbakt, and Klaritrosin. Extended-release formulations may carry additional designations such as SR, XL, Uno, or OD. Clarithromycin is included in combination packs for Helicobacter pylori eradication together with amoxicillin and a proton pump inhibitor, for example Prevpac and Omeclamox-Pak. Such packs must be taken into account when calculating the total dose: a patient may take clarithromycin separately while failing to recognize that it is also contained in an anti-Helicobacter combination regimen.

Why Clarithromycin Is Considered Harmless and Where the Real Risk Begins

Clarithromycin is often regarded as a familiar “antibiotic for a sore throat, bronchitis, or stomach problems,” although unsupervised use is dangerous for reasons extending far beyond allergy and digestive upset. The drug can prolong the QT interval, provoke ventricular arrhythmias, cause liver injury, and sharply alter the concentrations of other medicines through inhibition of CYP3A4 and the transport protein P-glycoprotein. The first signs of complications are nonspecific: weakness, nausea, dizziness, palpitations, bitterness, or an unusual taste in the mouth may mistakenly be attributed to the infection itself. Particularly dangerous situations include repeated use of leftover medication from an old course, use without a confirmed bacterial infection, and combination with statins, antiarrhythmic drugs, colchicine, anticoagulants, or several medications that affect cardiac rhythm. In patients with coronary artery disease, the FDA labeling separately notes a signal of a possible increase in long-term cardiovascular and all-cause mortality; therefore, the choice of this antibiotic in such patients requires specific justification.

Side Effects After the First Dose and During a Standard Course

Common reactions include diarrhea, nausea, abdominal pain, vomiting, dyspepsia, headache, and a pronounced alteration in taste — a metallic, bitter, or chemical taste. Reduced appetite, flatulence, candidiasis, and a temporary elevation of liver enzymes are also possible. These symptoms may appear after the first few doses and become more pronounced as the drug accumulates.

Clinically significant complications include drug-induced hepatitis, cholestasis with itching and jaundice, severe Clostridioides difficile-associated diarrhea, hearing impairment, confusion, agitation, insomnia, hallucinations, hypoglycemia due to interaction with glucose-lowering medications, and exacerbation of myasthenia gravis. Liver injury may develop within several days or weeks and, in rare cases, progress to liver failure.

Life-threatening reactions include anaphylaxis, angioedema, Stevens–Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome, acute generalized exanthematous pustulosis, fulminant liver injury, and torsades de pointes ventricular tachycardia. The risk of arrhythmia increases with congenital or acquired QT prolongation, bradycardia, hypokalemia, hypomagnesemia, heart failure, and concomitant use of other QT-prolonging agents.

Consequences of Long-Term and Repeated Use

Clarithromycin is usually prescribed in short courses; however, treatment of mycobacterial infections may continue for months. Long-term or repeated use increases the likelihood of persistent diarrhea, candidiasis, selection of resistant microorganisms, superinfection, and disruption of the intestinal microbiota. The antibiotic does not cause psychological or physical dependence, classical tolerance, or a withdrawal syndrome; however, repeated unjustified courses promote bacterial resistance: the drug continues to be taken, but the likelihood of a clinical effect decreases.

At high concentrations, with impaired liver or kidney function, or in the presence of drug interactions, cardiotoxic, hepatotoxic, and neurosensory effects may accumulate. Hearing impairment is usually reversible after discontinuation, but the risk increases with prolonged treatment, high doses, and combination with other ototoxic agents. Drug-induced liver injury usually regresses after the medication is stopped, although severe cases may lead to liver failure. C. difficile-associated diarrhea can occur not only during treatment but also weeks after the course has ended. The absence of significant reactions during the first few days does not guarantee that a repeated course will be tolerated in the same way: changes in concomitant medications, electrolyte disturbances, or deterioration of organ function may radically alter the toxicological profile.

Contraindications and High-Risk Groups

Clarithromycin is contraindicated in patients with confirmed hypersensitivity to clarithromycin, erythromycin, or other macrolides. It must not be prescribed again to a patient who previously developed clarithromycin-associated cholestatic jaundice or hepatic dysfunction: re-exposure may cause more rapid and severe liver injury.

The drug is contraindicated in congenital or documented acquired QT prolongation and in patients with a history of ventricular arrhythmia, including torsades de pointes. It is also clinically dangerous in severe bradycardia, decompensated heart failure, untreated hypokalemia, or hypomagnesemia. In patients with coronary artery disease, an alternative antibiotic should preferably be considered when it provides a comparable antibacterial effect.

In severe renal impairment, the dose must be reduced because elimination of clarithromycin and its active metabolite is decreased. The combination of severe renal and hepatic impairment is particularly dangerous because of drug accumulation. In older patients, the risk is further increased by polypharmacy, reduced glomerular filtration, and a higher prevalence of cardiac conduction abnormalities.

During pregnancy, clarithromycin is not an unequivocally preferred macrolide; it is used only after assessment of the benefits and risks, particularly during the first trimester. In patients with myasthenia gravis, the drug may worsen muscle weakness and impair breathing. Patients with a previous episode of antibiotic-associated diarrhea or colitis have a higher risk of recurrence.

Dangerous Drug Interactions

Contraindicated. Clarithromycin must not be combined with simvastatin or lovastatin: inhibition of CYP3A4 can increase their concentrations manyfold and create a risk of myopathy, rhabdomyolysis, hyperkalemia, and acute kidney injury. Combinations with ergotamine and dihydroergotamine are contraindicated because of the risk of severe vasospasm and ischemia of the limbs or central nervous system. Certain drugs that can prolong the QT interval and are simultaneously metabolized through CYP3A4 are also dangerous. Concomitant use with colchicine is contraindicated in patients with impaired liver or kidney function: fatal colchicine toxicity with bone marrow suppression, neuromyopathy, and multiple organ failure is possible.

Highly undesirable. Clarithromycin should not be combined without strict justification with amiodarone, sotalol, quinidine, procainamide, certain antipsychotics, methadone, hydroxychloroquine, and other QT-prolonging agents. The additive electrophysiological effects increase the likelihood of torsades de pointes and sudden death.

Requires dose adjustment or replacement. Atorvastatin and some other statins may also accumulate; temporary discontinuation, use of the lowest possible dose, or selection of a statin that is less dependent on CYP3A4 is preferable. Verapamil, diltiazem, amlodipine, and other calcium channel blockers may cause marked hypotension, bradycardia, and acute kidney injury when combined with clarithromycin. Oral midazolam and other sensitive CYP3A4 substrates may cause excessive sedation and respiratory depression.

Requires laboratory or instrumental monitoring. When clarithromycin is combined with warfarin or other anticoagulants, the risk of bleeding may increase — INR or the appropriate coagulation parameters must be monitored. Clarithromycin can increase digoxin concentrations by inhibiting P-glycoprotein; pulse, ECG, and, where possible, digoxin concentrations should be monitored. When combined with insulin or sulfonylurea derivatives, glucose monitoring is required because of the risk of hypoglycemia. Carbamazepine, theophylline, cyclosporine, tacrolimus, and a number of antiretroviral drugs may also require dose adjustment and therapeutic drug monitoring.

Alcohol does not cause a classic disulfiram-like reaction with clarithromycin; however, it is highly undesirable during treatment: it may worsen nausea, dizziness, dehydration, and the burden on the liver, and may also interfere with adherence to the dosing regimen. St. John’s wort can induce CYP3A4 and reduce exposure to some drugs; combining it with antibacterial therapy without reviewing the entire medication regimen is inappropriate. Hidden duplication may occur when a patient takes separate clarithromycin together with a ready-made anti-Helicobacter combination pack.

Patient Errors

The main mistake is starting clarithromycin for a viral infection, a cough without an established bacterial cause, a sore throat without diagnostic confirmation, or “just in case.” Increasing the dose when rapid improvement does not occur does not broaden the antimicrobial spectrum; it only raises the drug concentration and increases the risk of arrhythmia, diarrhea, hepatotoxicity, and drug interactions.

The intervals between doses must not be shortened, a missed dose must not be compensated for with a double dose, and the course must not be prolonged independently. Reusing an old prescription is particularly dangerous if new medications have been added since the previous course: a statin, anticoagulant, antiarrhythmic drug, colchicine, digoxin, or calcium channel blocker.

It is incorrect to stop treatment immediately after fever or pain decreases if the course was prescribed for a confirmed indication: this increases the risk of treatment failure and selection of resistant bacteria. It is equally wrong to continue the drug if jaundice, dark urine, fainting, pronounced palpitations, blistering skin rash, or facial swelling develops. A familiar brand name, a previously well-tolerated course, or use of the medication by other family members does not confirm that it is safe for this particular patient with this particular set of concomitant medications.

Overdose and Poisoning

No single acute or cumulative dose has been established that causes severe poisoning in all patients. Toxicity depends on the dosage form, age, body weight, liver and kidney function, electrolyte balance, and drug interactions. Even a standard therapeutic dose may become dangerous in severe renal impairment, marked hypokalemia, combination with CYP3A4-inhibited substrates, or concomitant use of QT-prolonging medications.

During the first hours after an excessive dose, the most likely symptoms are abdominal pain, pronounced nausea, repeated vomiting, and diarrhea. Headache, confusion, agitation, and hearing impairment may occur. Against the background of dehydration and electrolyte loss, the risk of arrhythmia may increase further. Later, attention should be directed to signs of liver injury, impaired kidney function, persistent diarrhea, and toxicity of other drugs taken at the same time.

Hidden overdose can develop after taking a double dose following a missed dose, confusion between immediate-release and extended-release tablets, incorrect preparation of a suspension, an error in calculating a pediatric dose, or simultaneous use of separate clarithromycin and a combination anti-Helicobacter pack.

There is no specific antidote. Treatment includes early removal of medication that has not yet been absorbed, when deemed appropriate by a medical professional, symptomatic and supportive therapy, and monitoring of ECG, electrolytes, liver function, and kidney function. Hemodialysis and peritoneal dialysis do not provide clinically significant removal of clarithromycin. Waiting for severe symptoms to appear is dangerous: in interactions with a statin, colchicine, digoxin, or an antiarrhythmic drug, the severity of the condition may be determined not only by the antibiotic itself but also by rapid accumulation of the second medication.

Integrative Alternative and Recovery After Clarithromycin

For mild or moderate uncomplicated inflammation of the upper respiratory tract, when there are no signs of pneumonia, bacterial sinusitis with a risk of complications, streptococcal tonsillitis, severe systemic infection, or another condition requiring an antibiotic, Andrographis paniculata may be considered as the main herbal preparation. Clinical studies and meta-analyses show that standardized andrographis preparations can reduce sore throat, nasal congestion, headache, general malaise, and the duration of symptoms of an acute respiratory infection. However, the quality of the studies is heterogeneous, and a confirmed ability to eradicate a specific bacterial pathogen at a level comparable to clarithromycin has not been established. Therefore, andrographis can be a full alternative only when an antibiotic is not indicated in the first place, and not when a confirmed bacterial infection requires antibacterial treatment.

As an additional anti-inflammatory complex in mild uncomplicated cases, Japanese honeysuckle, Forsythia suspensa, and plukao — Houttuynia cordata may be used. Their use should be described as phytotherapeutic anti-inflammatory and symptomatic support, not as a guaranteed replacement for clarithromycin in bacterial pneumonia, mycobacterial infection, severe sinusitis, or Helicobacter pylori eradication.

The main integrative approach after a course of clarithromycin is not an attempt to immediately replace one antimicrobial agent with another, but restoration of the intestinal barrier, mucous membranes, metabolic resilience, and liver function. Clarithromycin is metabolized predominantly by the CYP3A4 system, can cause drug-induced cholestatic or hepatocellular hepatitis, and can substantially alter the concentrations of other drugs. Most episodes of drug-induced liver injury regress after discontinuation, but severe hepatocellular damage may progress to acute liver failure.

A metal and xenobiotic elimination support complex may be considered as a restorative approach after completion of antibiotic therapy, but not as an antidote and not as a means proven to accelerate the elimination of clarithromycin. Its use should take into account the composition of the complex, liver and kidney function, concomitant medications, and the likelihood of additional interactions.

Milk thistle — Silybum marianum may be used as part of a hepatoprotective and antioxidant approach after the course, especially in the presence of dyspepsia or a moderate elevation of liver enzymes after ongoing drug-induced hepatitis has been excluded. Milk thistle should not mask the need to discontinue the drug in the presence of jaundice, dark urine, severe itching, or rising bilirubin. Turmeric — Curcuma longa and Rehmannia glutinosa may complement an anti-inflammatory and antioxidant approach, but they should not be introduced simultaneously with a large number of other agents without assessing drug interactions.

Colostrum may be used to support restoration of the intestinal barrier after antibiotic-associated disruption of the microbiota. Clinical studies in selected patient groups suggest a potential reduction in intestinal permeability, but these results cannot automatically be extrapolated to the treatment of antibiotic-associated diarrhea or Clostridioides difficile infection. In the presence of watery stools, fever, abdominal pain, or blood in the stool, colostrum does not replace diagnosis and specific treatment.

Lion’s mane — Hericium erinaceus may be included in a program to support the gastrointestinal mucosa, Centella asiatica may be used to support restoration of microcirculation and damaged tissues, and tinder fungus extract may be used as part of an antioxidant and metabolic approach. These agents serve a restorative rather than antibacterial function.

Coptis chinensis and barberry contain berberine alkaloids and should not automatically be combined with clarithromycin. Both approaches can affect enzymes and transport systems involved in drug metabolism; therefore, against the background of strong inhibition of CYP3A4 and P-glycoprotein by clarithromycin itself, the unpredictability of interactions increases. It is more appropriate to consider them after completion of the course and after reviewing the entire medication regimen.

Orthosiphon may be used when there are independent indications involving the urinary system, but it is not an obligatory component of recovery after clarithromycin. Unlike neomycin, clarithromycin is not a typical directly nephrotoxic aminoglycoside. Renal risk is more often associated with accumulation of the drug when filtration is reduced, dehydration, rhabdomyolysis due to interaction with statins, or hypotension when combined with calcium channel blockers.

Real Effectiveness of Clarithromycin and Prescribing Errors

Clarithromycin is genuinely effective against susceptible bacterial pathogens and is used for certain infections of the respiratory tract, skin and soft tissues, mycobacterial infections, as well as in combination regimens for Helicobacter pylori eradication. It acts on bacterial protein synthesis, but it does not treat viral infections, allergic inflammation, post-infectious cough, or most episodes of uncomplicated acute bronchitis.

When the pathogen is susceptible, clinical improvement usually begins to appear within the first few days; however, disappearance of fever or pain does not mean immediate eradication of the infection. With a resistant microorganism, increasing the dose or extending the course does not turn an ineffective antibiotic into an effective one — it only increases the toxicological burden.

For Helicobacter pylori, clarithromycin must not be considered a stand-alone treatment. It is used only as part of a combination regimen. The effectiveness of clarithromycin-containing regimens depends strongly on local bacterial resistance and previous macrolide exposure. Prescribing standard triple therapy without taking these factors into account may expose the patient to all of clarithromycin’s drug interactions without achieving successful eradication.

Common prescribing errors include use for viral infection, failure to assess prior macrolide exposure, ignoring ECG findings and electrolyte abnormalities in a patient at risk of arrhythmia, failure to check statins, colchicine, digoxin, anticoagulants, and antiarrhythmic drugs, and use of a standard dose in patients with markedly reduced kidney function. Clarithromycin is an effective antibiotic, but only when there is a susceptible bacterial target. In the absence of such a target, its pharmacological activity remains impressive mainly with regard to CYP3A4 and its extensive list of interactions.

Safety Monitoring During Treatment

Before prescribing, a complete list of medications should be obtained, including temporarily used drugs, dietary supplements, and herbal preparations. In a patient with cardiovascular disease, fainting, arrhythmia, marked bradycardia, or concomitant use of QT-prolonging agents, a baseline ECG and assessment of potassium and magnesium are advisable. Clarithromycin should be avoided in known QT prolongation, ventricular arrhythmias, uncorrected hypokalemia or hypomagnesemia, significant bradycardia, and in patients taking class IA or class III antiarrhythmic drugs.

Creatinine and estimated glomerular filtration rate should be assessed before treatment in older patients, in those with kidney disease, dehydration, or a prolonged course. With marked reduction in kidney function, the dose must be reduced or the interval between doses increased.

ALT, AST, alkaline phosphatase, gamma-glutamyl transferase, and bilirubin should be tested in patients with pre-existing liver disease, prolonged treatment, or the appearance of nausea, marked weakness, loss of appetite, pain in the right upper quadrant, itching, jaundice, dark urine, or pale stools. If clinical signs of hepatitis appear, clarithromycin is discontinued. The typical pattern of injury is cholestatic hepatitis, but a more severe hepatocellular form with acute liver failure is also possible.

With concomitant warfarin, INR and signs of bleeding should be monitored; with digoxin — pulse, ECG, and, if possible, its concentration; with sulfonylurea derivatives or insulin — blood glucose; with tacrolimus, cyclosporine, carbamazepine, and other drugs with a narrow therapeutic range — their concentrations and toxicity profiles.

Immediate discontinuation and urgent evaluation are required in cases of fainting, sudden palpitations, irregular heartbeat, severe dizziness, seizures, difficulty breathing, swelling of the face or larynx, widespread rash, blistering or skin detachment, jaundice, confusion, rapidly worsening muscle weakness, a sharp reduction in urine output, and severe diarrhea. Waiting is particularly dangerous in torsades de pointes, anaphylaxis, severe skin reactions, rhabdomyolysis, or drug-induced liver injury: initially moderate symptoms can rapidly progress to a life-threatening condition.

Proper Discontinuation

Clarithromycin does not cause a pharmacological withdrawal syndrome and does not require gradual dose reduction. In the event of a severe allergic reaction, jaundice, suspected drug-induced hepatitis, marked arrhythmia, or a severe skin reaction, the drug is discontinued immediately.

During routine treatment of a confirmed bacterial infection, the course should not be stopped independently after the first signs of improvement. Premature discontinuation may lead to persistence of the pathogen, recurrence of infection, and selection of resistant bacteria. At the same time, the drug should not be continued mechanically until the last tablet if signs of serious toxicity appear: safety takes priority, and the subsequent antibacterial regimen should be determined by a specialist.

A missed dose should be taken once the omission is noticed, provided that the next scheduled dose is not already approaching. The dose must not be doubled. With extended-release tablets, it is especially important not to alter the regimen independently or replace them with an equal number of immediate-release tablets without recalculating the regimen.

After completion of the course, altered taste, dyspepsia, unstable stools, and moderate microbiota disturbances may persist. C. difficile-associated diarrhea may first appear after the antibiotic has already been discontinued, so persistent watery diarrhea, fever, and abdominal pain should not be regarded as ordinary “intestinal recovery.”

A Reasonable Approach to Treatment

Clarithromycin is justified when an established or reasonably suspected bacterial disease is susceptible to the drug and the expected benefit outweighs the risks of arrhythmia, hepatotoxicity, and drug interactions. It may be necessary for certain respiratory, mycobacterial, and other infections, as well as a component of a properly selected H. pylori eradication regimen.

In mild uncomplicated inflammation without proven bacterial origin, it is preferable not to prescribe an antibiotic at all. In such situations, andrographis, honeysuckle, forsythia, and houttuynia may be used as anti-inflammatory and symptomatic phytotherapy, with mandatory monitoring of the patient’s condition.

After a course of clarithromycin, an integrative program should focus on recovery rather than on endlessly continuing antimicrobial treatment. Priority areas include support of the liver, intestinal barrier, and mucous membranes, correction of nutrition and fluid intake, restoration of the microbiota, and reduction of polypharmacy. A xenobiotic elimination support complex, milk thistle, colostrum, turmeric, lion’s mane, and centella may be included selectively, based on the clinical consequences of treatment rather than by simultaneously prescribing the entire available range of herbal products.

Concomitant use of clarithromycin with herbal preparations is acceptable only after potential interactions have been reviewed. In particular, uncontrolled addition of coptis, barberry, concentrated berberine preparations, and multicomponent complexes affecting CYP3A4 or P-glycoprotein is especially undesirable during the course. The goal of an integrative approach is not to reject antibiotics, but to use them only for confirmed indications, minimize the toxicological burden, and ensure full recovery after treatment.

If you have questions related to this article, you can ask a clinical pharmacologist in the comments or schedule a consultation using the following link: https://asiabiopharm.com/konsultaciii/